Cue Biopharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CUE Nasdaq 2836 www.cuebiopharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cue Biopharma, Inc.

Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments - May 14th, 2026 2:07 pm
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7th, 2026 5:07 pm
Cue Biopharma Announces $30 Million Private Placement - Apr 30th, 2026 2:25 pm
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody - Apr 30th, 2026 2:15 pm
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company - Apr 30th, 2026 2:05 pm
Cue Biopharma Announces 1-for-30 Reverse Stock Split - Apr 22nd, 2026 6:37 am
Cue Biopharma (CUE) Appoints Lucinda Warren as Interim President and CEO - Apr 20th, 2026 8:15 am
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 - Apr 15th, 2026 6:00 am
The VIX Sharply Reverses and Points Back Towards 30 After Failed Peace Negotiations - Apr 13th, 2026 8:16 am
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement - Apr 8th, 2026 6:00 am
Cue Biopharma Announces CEO Transition - Mar 27th, 2026 2:05 pm
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026 - Mar 26th, 2026 6:00 am
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Mar 16th, 2026 2:05 pm
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - Mar 9th, 2026 6:00 am
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases - Feb 17th, 2026 6:00 am
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer - Feb 12th, 2026 6:00 am
Cue Biopharma Announces Pricing of $10 Million Public Offering - Dec 19th, 2025 6:00 am
Cue Biopharma Announces Proposed Public Offering - Dec 18th, 2025 2:02 pm
Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments - Nov 13th, 2025 11:10 am
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates - Nov 12th, 2025 3:25 pm